Day: August 3, 2021

$9.3 billion asset community bank using nCino’s cloud-based, single platform to enable automated workflow across the institution WILMINGTON, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced that S&T Bank is now live on the nCino Bank Operating System®. With a footprint spanning Pennsylvania, Ohio and New York, the community bank selected and adopted nCino to streamline processes, advance their digital strategy and better serve their business clients. Through nCino, S&T has been able to eliminate numerous disparate systems and manual processes in favor of a single, end-to-end platform through nCino’s Commercial and Small Business Lending Solutions. S&T is now also live...

TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2021 financial and operating results on Tuesday, August 10, 2021 before the market opens. The company will also host a conference call on Tuesday, August 10, 2021 at 10:00 a.m. Eastern Time. To access the call live, please dial 416-406-0743 or 1-800-952-5114 and use access code 2381183#. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Tuesday, August 17, 2021 by dialing 905-694-9451 or 1-800-408-3053, using access code:9081508#. About Acerus Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of...

– OpGen subsidiary Curetis and its instrument development partner have completed assembly of 10 final pre-series release A30 RQ analyzers – Unyvero A30 RQ instruments are now readily available for final verification and validation testing ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program. The A30 RQ analyzers will now proceed into final...

BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat as part of the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET. The Company will also host investor meetings during the conference. If you are interested in arranging a one-on-one meeting or listening to the live event, please contact your BTIG conference representative. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. The Company is developing its own internal portfolio of products as well as partnering with leading...

Financial Highlights:Total Revenue Grew 27% Propelled by Streaming Acceleration and Partial Recovery in Certain COVID-Impacted Areas Recorded Music Streaming Revenue Grew 27% Powered by Chart-Topping New Music Robust Growth in Revenue from Emerging Streaming Platforms Margin Expansion and High Operating Cash Flow Conversion Driven by Strong Operating LeverageFor the three months ended June 30, 2021Total revenue grew 33% or 27% in constant currency Digital revenue grew 29% or 23% in constant currency Net income was $61 million versus net loss of $519 million in the prior-year quarter OIBDA was income of $241 million versus a loss of $371 million in the prior-year quarter Adjusted OIBDA increased 58% to $263 million versus $166 million in the prior-year quarter Adjusted EBITDA increased 49% to $282 million versus $189 million in the...

Table 1Kennecott Rock Chip Sample Results near American PitFigure 1Location of samples taken from the past two sampling campaignsVANCOUVER, British Columbia, Aug. 03, 2021 (GLOBE NEWSWIRE) — American Pacific Mining Corp (CSE: USGD / OTCQB: USGDF / FWB: 1QC) (“American Pacific” or the “Company”) is pleased to announce results from a sampling program at the Company’s flagship Madison Copper-Gold project (the “Madison Project”) in Montana, USA. American Pacific has a joint venture earn-in agreement with Rio Tinto, whereby Rio Tinto may spend US $30 million to earn up to 70% of the Madison Project. A total of 26 rock chip samples were collected near the past producing American pit, which identified significant high-grade gold (Au) and copper (Cu) mineralization at the Madison Project. These samples...

WILMINGTON, Del., Aug. 03, 2021 (GLOBE NEWSWIRE) — Ashland Global Holdings Inc. (NYSE: ASH) today announced the intention of its indirect, wholly owned subsidiary Ashland LLC to offer $450 million aggregate principal amount of senior notes (the “Notes”). The Notes will be senior unsecured obligations of Ashland LLC. The Notes will initially be guaranteed on an unsecured basis by Ashland Global Holdings Inc. (the “Guarantee”). Ashland intends to use the net proceeds of the offering (after deducting initial purchasers’ discounts and other fees and expenses) to redeem its obligations under its outstanding 4.750 percent senior notes due 2022, and to pay any premiums, penalties, fees and expenses associated therewith (the “Refinancing”), with any remaining net proceeds to be held as cash on the balance sheet and used for general corporate...

— Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies —— Setmelanotide selected for evaluation as a “Highly Specialised Technology” by Great Britain’s National Institute for Health and Care Excellence —— On track to submit sNDA to FDA and MAA Type II amendment to EMA for setmelanotide in BBS and Alström syndromes in 2H 2021 —— Five new Phase 2 and 3 clinical trials planned to initiate in 2H 2021 —— Management to host conference call at 8 a.m. ET — BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today reported...